收稿日期: 2022-08-22
网络出版日期: 2022-12-19
基金资助
中华国际医学交流基金会基金(Z-2018-40-2101);北京大学人民医院研究与发展基金(RDE 2021-18)
罗靓 , 蔡青猛 , 刘香君 , 贠泽霖 , 李春 , 张晓盈 . 以雷诺现象为首发表现的系统性硬化症临床特征及其相关因素[J]. 北京大学学报（医学版）, 2022 , 54(6) : 1224 -1228 . DOI: 10.19723/j.issn.1671-167X.2022.06.028
| 1 | Wigley FM , Flavahan NA . Raynaud's phenomenon[J]. N Engl J Med, 2016, 375 (6): 556- 565. |
| 2 | Pauling JD , Hughes M , Pope JE . Raynaud's phenomenon: An update on diagnosis, classification and management[J]. Clin Rheumatol, 2019, 38 (12): 3317- 3330. |
| 3 | 刘晶, 史群, 徐东, 等. 雷诺现象为首发表现的自身免疫性疾病疾病谱及临床特点[J]. 中华临床免疫和变态反应杂志, 2013, 7 (4): 346- 350. |
| 4 | Schneeberger D , Tyndall A , Kay J , et al. Systemic sclerosis without antinuclear antibodies or Raynaud's phenomenon: A multicentre study in the prospective EULAR scleroderma trials and research (EUSTAR) database[J]. Rheumatology (Oxford), 2013, 52 (3): 560- 567. |
| 5 | Walker UA , Tyndall A , Czirják L , et al. Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR scleroderma trials and research group database[J]. Ann Rheum Dis, 2007, 66 (6): 754- 763. |
| 6 | Matucci-Cerinic M , Kahaleh B , Wigley FM . Review: Evidence that systemic sclerosis is a vascular disease[J]. Arthritis Rheum, 2013, 65 (8): 1953- 1962. |
| 7 | Bairkdar M , Rossides M , Westerlind H , et al. Incidence and prevalence of systemic sclerosis globally: A comprehensive syste-matic review and meta-analysis[J]. Rheumatology (Oxford), 2021, 60 (7): 3121- 3133. |
| 8 | Galetti I , Nunzio SD , Brogelli L , et al. How do systemic sclerosis manifestations influence patients' lives? Results from a survey on patients and caregivers[J]. Curr Med Res Opin, 2021, 37 (Suppl 2): 5- 15. |
| 9 | Elhai M , Meune C , Boubaya M , et al. Mapping and predicting mortality from systemic sclerosis[J]. Ann Rheum Dis, 2017, 76 (11): 1897- 1905. |
| 10 | Preliminary criteria for the classification of systemic sclerosis (scleroderma) . Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee[J]. Arthritis Rheum, 1980, 23 (5): 581- 590. |
| 11 | van den Hoogen F , Khanna D , Fransen J , et al. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative[J]. Ann Rheum Dis, 2013, 72 (11): 1747- 1755. |
| 12 | Bussone G , Mouthon L . Interstitial lung disease in systemic sclerosis[J]. Autoimmun Rev, 2011, 10 (5): 248- 255. |
| 13 | Simonneau G , Robbins IM , Beghetti M , et al. Updated clinical classification of pulmonary hypertension[J]. J Am Coll Cardiol, 2009, 54 (Suppl 1): S43- S54. |
| 14 | Bruni C , De Luca G , Lazzaroni MG , et al. Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review[J]. Eur J Intern Med, 2020, 78, 17- 25. |
| 15 | Denton CP , Khanna D . Systemic sclerosis[J]. Lancet, 2017, 390 (10103): 1685- 1699. |
| 16 | Maciejewska M , Sikora M , Maciejewski C , et al. Raynaud's phenomenon with focus on systemic sclerosis[J]. J Clin Med, 2022, 11 (9): 2490. |
| 17 | Rubio-Rivas M , Corbella X , Pestaóa-Fernández M , et al. First clinical symptom as a prognostic factor in systemic sclerosis: Results of a retrospective nationwide cohort study[J]. Clin Rheumatol, 2018, 37 (4): 999- 1009. |
| 18 | Launay D , Sitbon O , Hachulla E , et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era[J]. Ann Rheum Dis, 2013, 72 (12): 1940- 1946. |
| 19 | Nihtyanova SI , Schreiber BE , Ong VH , et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis[J]. Arthritis Rheumatol, 2014, 66 (6): 1625- 1635. |
| 20 | Wise RA , Wigley F , Newball HH , et al. The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon[J]. Chest, 1982, 81 (6): 695- 698. |
| 21 | Wangkaew S , Pota P , Prasertwittayakij N , et al. Incidence, predictors, and survival of pulmonary hypertension determined by echocardiography in Thai patients with early systemic sclerosis (SSc): Inception cohort study[J]. Clin Rheumatol, 2021, 40 (3): 973- 980. |
| 22 | Perelas A , Silver RM , Arrossi AV , et al. Systemic sclerosis-associated interstitial lung disease[J]. Lancet Respir Med, 2020, 8 (3): 304- 320. |
| 23 | Khanna D , Nagaraja V , Tseng CH , et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials[J]. Arthritis Res Ther, 2015, 17, 372. |
| 24 | Rubio-Rivas M , Royo C , Simeón CP , et al. Mortality and survival in systemic sclerosis: Systematic review and meta-analysis[J]. Semin Arthritis Rheum, 2014, 44 (2): 208- 219. |
| 25 | Meunier P , Dequidt L , Barnetche T , et al. Increased risk of mortality in systemic sclerosis-associated digital ulcers: A systematic review and meta-analysis[J]. J Eur Acad Dermatol Venereol, 2019, 33 (2): 405- 409. |
| 26 | Bering J , Griffing WL , Crowell M , et al. Progression of gastrointestinal symptoms over time in patients with systemic sclerosis[J]. Rheumatol Int, 2021, 41 (7): 1281- 1287. |
| 27 | Steelandt A , Benmostefa N , Avouac J , et al. Ethnic influence on the phenotype of French patients with systemic sclerosis[J]. Joint Bone Spine, 2021, 88 (2): 105081. |
| 28 | Kowal-Bielecka O , Fransen J , Avouac J , et al. Update of EULAR recommendations for the treatment of systemic sclerosis[J]. Ann Rheum Dis, 2017, 76 (8): 1327- 1339. |
/
| 〈 |
|
〉 |
